Intra Cellular Therapies reported $5.85M in Cost of Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US USD 2.14M 531K
ALKERMES ALKS:US USD 50.62M 7.74M
Biocryst Pharmaceuticals BCRX:US USD 3.61M 3.37M
Biogen BIIB:US USD 469.5M 14.5M
Bristol Myers Squibb BMY:US USD 2.35B 324M
Esperion Therapeutics ESPR:US USD 6.51M 2.67M
Gilead Sciences GILD:US USD 1.4B 47M
Halozyme Therapeutics HALO:US USD 47.32M 13.38M
Intra Cellular Therapies ITCI:US USD 5.85M 1.2M
JAZZ PHA JAZZ:US USD 133.66M 9.45M
Johnson & Johnson JNJ:US USD 7.81B 95M
Nektar Therapeutics NKTR:US USD 4.97M 143K
Neurocrine Biosciences NBIX:US USD 6.1M 1.3M
Novartis NVS:US USD 3.66B 92M
Supernus Pharmaceuticals SUPN:US USD 25.88M 5.42M
United Therapeutics UTHR:US USD 37.2M 7.5M
Vanda Pharmaceuticals VNDA:US USD 6.32M 261K